- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02996630
Assessing Neurodevelopment in Congenital Heart Disease. (NEUROHEART)
Abnormal Neurodevelopment Detection in Congenital Heart Disease: Predictive Methods Based on Prenatal and Postnatal Factors.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The main objectives of this study are: 1. to describe the neurodevelopmental outcome of patients with CHD at 24 months of age; 2. identify the subgroup with poorer outcome; and 3. evaluate the utility of fetal and postnatal diagnostic techniques for early detection of patients at risk for altered neurological outcomes.
Seven Spanish referral centers for CHD included in the research network on maternal and child health currently participating in this prospective multicentric case-control coordinated study. Fetuses with CHD (transposition of great arteries, tetralogy of Fallot, hypoplastic left heart syndrome and septal defects) will be studied from 24 weeks of gestation to 2 years of age. Diagnostic tests will be repeated throughout the study in all patients, from the fetal period to 24 months of age, and will include: fetal cerebral hemodynamic Doppler assessment, functional echocardiography, brain MRI, regional cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers analysis. Neurodevelopmental assessment will be made at 12 months of age using the ages and stages questionnaire (ASQ) and at 24 months of age with the Bayley-III test. From this data, statistical analysis will select the most useful as predictors of damage; to be then combined and create algorithms for predicting brain damage and poor neurodevelopment. Once description has been made, we will proceed to identify amongst our results, children with the poorest neurological outcome and remark possible common prenatal and early life markers in them as well as the CHD severity they present.
While advances in early diagnosis and postnatal management have increased survival in CHD children, worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor in the counseling of these pregnancies. Evidence available does not allow clinicians to assess on neurological prognosis although has opened up the possibility of finding prenatal markers of brain damage. Even though, no prospective studies have been performed until now. We present a multicentric prospective study able to recruit enough fetal CHD affected pregnancies to obtain neurological prognostic tools.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Barcelona, Spanien, 08035
- Rekrutierung
- Hospital Universitari Vall d'Hebron
-
Kontakt:
- Irene Ribera, Dr
- Telefonnummer: 3086 934893000
- E-Mail: irene.ribera@vhir.org
-
Kontakt:
- Elisa Llurba, Dr
- Telefonnummer: 3086 934893000
- E-Mail: irene.ribera@vhir.org
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Single pregnancies
- Major Congenital Heart Disease
- Informed Consent Signed
Exclusion Criteria:
- Major extra-cardiac malformations
- Parental Refusal to participate
- Maternal Chronic Disease
- Multiple Pregnancies
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Sonstiges: Healthy fetuses
Pregnant patients carrying a healthy fetus.
Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
|
Fetal Ultrasound exploration
Fetal MRI for brain study
Neurodevelopment paediatric assessment test performed at 2 years of age.
Cord blood samples will be taken after birth in both groups.
|
|
Sonstiges: Congenital Hearth Disease
Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
|
Fetal Ultrasound exploration
Fetal MRI for brain study
Neurodevelopment paediatric assessment test performed at 2 years of age.
Cord blood samples will be taken after birth in both groups.
Congenital Heart Disease repair
EEG and continuous brain oximetry before surgery.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Bailey-III test punctuation
Zeitfenster: 45 minutes
|
Results in pediatric Bailey-III test scale
|
45 minutes
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Biparietal diameter (mm)
Zeitfenster: one day
|
Biparietal diameter (mm) measured with MRI
|
one day
|
|
Lateral sulcus depth
Zeitfenster: one day
|
Lateral sulcus depth (mm) measured with MRI
|
one day
|
|
Cerebral insula
Zeitfenster: one day
|
Insula (mm) measured with MRI
|
one day
|
|
Brain biometries
Zeitfenster: one day
|
Calcarine sulcus depth (mm)
|
one day
|
|
Cerebral cingulata sulcus
Zeitfenster: one day
|
Cingulata sulcus depth (mm) measured with MRI
|
one day
|
|
Corpus callosum
Zeitfenster: one day
|
Corpus callosum (mm) measured with MRI
|
one day
|
|
Cerebellum
Zeitfenster: one day
|
Cerebellum vermis (mm) measured with MRI
|
one day
|
|
Umbilical doppler
Zeitfenster: one day
|
Umbilical artery pulsatility index
|
one day
|
|
Middle cerebral artery doppler
Zeitfenster: one day
|
Middle cerebral artery pulsatility index
|
one day
|
|
Angiogenic PLGF (placental growth factor)
Zeitfenster: Two days
|
Placental growth factor in maternal serum
|
Two days
|
|
Angiogenic s-FLt (soluble fms-like tyrosine kinase)
Zeitfenster: Two days
|
Soluble fms-like tyrosine kinase factor in maternal serum
|
Two days
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienleiter: Elisa Llurba, MD, PhD, Hospital Universitari Vall d'Hebron
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002 Jun 19;39(12):1890-900. doi: 10.1016/s0735-1097(02)01886-7.
- Bellinger DC, Jonas RA, Rappaport LA, Wypij D, Wernovsky G, Kuban KC, Barnes PD, Holmes GL, Hickey PR, Strand RD, et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. N Engl J Med. 1995 Mar 2;332(9):549-55. doi: 10.1056/NEJM199503023320901.
- Limperopoulos C, Majnemer A, Shevell MI, Rosenblatt B, Rohlicek C, Tchervenkov C. Neurodevelopmental status of newborns and infants with congenital heart defects before and after open heart surgery. J Pediatr. 2000 Nov;137(5):638-45. doi: 10.1067/mpd.2000.109152.
- Masoller N, Martinez JM, Gomez O, Bennasar M, Crispi F, Sanz-Cortes M, Egana-Ugrinovic G, Bartrons J, Puerto B, Gratacos E. Evidence of second-trimester changes in head biometry and brain perfusion in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2014 Aug;44(2):182-7. doi: 10.1002/uog.13373. Epub 2014 Jul 8.
- Ruiz A, Cruz-Lemini M, Masoller N, Sanz-Cortes M, Ferrer Q, Ribera I, Martinez JM, Crispi F, Arevalo S, Gomez O, Perez-Hoyos S, Carreras E, Gratacos E, Llurba E. Longitudinal changes in fetal biometry and cerebroplacental hemodynamics in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2017 Mar;49(3):379-386. doi: 10.1002/uog.15970.
- Ribera I, Ruiz A, Sanchez O, Eixarch E, Antolin E, Gomez-Montes E, Perez-Cruz M, Cruz-Lemini M, Sanz-Cortes M, Arevalo S, Ferrer Q, Vazquez E, Vega L, Dolader P, Montoliu A, Boix H, Simoes RV, Masoller N, Sanchez-de-Toledo J, Comas M, Bartha JM, Galindo A, Martinez JM, Gomez-Roig L, Crispi F, Gomez O, Carreras E, Cabero L, Gratacos E, Llurba E. Multicenter prospective clinical study to evaluate children short-term neurodevelopmental outcome in congenital heart disease (children NEURO-HEART): study protocol. BMC Pediatr. 2019 Sep 10;19(1):326. doi: 10.1186/s12887-019-1689-y.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- PR(AMI)317/2012
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .